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Fourth Military Medical University, Xi’an, ChinaAbstractWe previously demonstrated that pretreatment quantitative anti–hepatitis B core protein (qAnti-HBc) levels can predict the treatment
response for both interferon and nucleoside analogue therapy, but the characteristics of qAnti-HBc during chronic hepatitis B virus
(HBV) infection remain poorly understood. To understand this issue, the qAnti-HBc levels were evaluated in individuals with past HBV
infection, occult HBV infection and chronic HBV infection in the immune tolerance phase, immune clearance phase, low-replicative phase
and hepatitis B e antigen (HBeAg)-negative hepatitis phase. Individuals with hepatitis B surface antigen (n = 598, 3.74 ± 0.90 log10 IU/mL)
had signiﬁcantly higher (p < 0.001, approximately 1000-fold) serum qAnti-HBc levels than those who had occult HBV, and serum qAnti-
HBc levels were signiﬁcantly higher in the occult HBV group than in the past HBV infection group (p < 0.001). qAnti-HBc levels were
positively correlated with alanine aminotransferase levels (R = 0.663, p < 0.001), and subjects with an abnormal alanine aminotransferase
level had a higher qAnti-HBc level (p < 0.001). Serum qAnti-HBc level varied in different phases of HBV infection, as determined by host
immune status. Serum qAnti-HBc level is strongly associated with hepatitis activity in subjects with chronic HBV infection.
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iable and complex. Chronic HBV infection (CHB) can typically
be divided into four phases on the basis of the characteristics of
the host immune response and the virus: the immune tolerance
phase (IT), the immune clearance phase (IC), the low-
replicative phase (LR) and the hepatitis B e antigen (HBeAg)-
negative hepatitis (ENH) phase [1,2]. Knowledge of the natural
history of HBV infection is essential for the improvement of the
clinical management of HBV-related liver disease and for a
better understanding of the underlying pathogenic mechanisms
of HBV infection. Several studies have examined the use ofClin Microbiol Infect 2015; 21: 197–203
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
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tools for the prediction of treatment response and disease
progression, such as quantitative hepatitis B surface antigen
(HBsAg) and HBeAg [3–7]. However, practical biomarkers and
assays that can be used to characterize host immune readiness
against HBV remain lacking.
Hepatitis B core protein antibody (Anti-HBc) is a classical
serologic HBV marker that has been clinically used for more
than 35 years [8]. However, the clinical signiﬁcance of quanti-
tative anti-HBc (qAnti-HBc) measurements has not been
carefully investigated. With a novel double-sandwich anti-HBc
quantitative immunoassay [9], we recently demonstrated that
the pretreatment anti-HBc level is a potential new predictor for
treatment response in both adefovir dipivoxil and peginterferon
therapy [10], and it is the strongest predictor for 2-year HBeAg
seroconversion in HBeAg-positive subjects treated with telbi-
vudine alone or in combination with adefovir [11]. This new
ﬁnding highlights the prognostic value of the qAnti-HBc level in
CHB subjects. However, the proﬁles and the dynamics of the
anti-HBc level during the natural course of HBV infection are
still largely unknown.MethodsSubjects and cohorts
A cross-sectional cohort consisting of three groups was stud-
ied. The ﬁrst group included samples from 535 healthy in-
dividuals with serologic evidence of past HBV infection (PBI)
collected from the Xiamen Blood Service. All PBI individuals
were HBsAg negative, HBV DNA negative and Anti-HBc posi-
tive, and had alanine aminotransferase (ALT) values less than
the upper limit of normal. The second group included 56 blood
donors with occult HBV infection (OBI) who were anti-HBc
positive, HBsAg negative and HBV DNA positive, and who
were part of a previously described OBI cohort (n = 61)
identiﬁed from 38 499 blood donors by nucleic acid testing
[12]. The third group included a total of 598 subjects with CHB,
316 of whom were from Zhongshan Hospital (Xiamen, China)
and 282 of whom were from Xijing Hospital (Xi’an, China). All
subjects were positive for HBsAg over a 6-month period; were
negative for anti–human immunodeﬁciency virus, anti–hepatitis
C virus, anti–hepatitis D virus and other markers of coexistent
autoimmune or metabolic liver disease; and were treatment
naïve or had a treatment-free interval of >1 year at the time of
enrollment. All the subjects with evidence of liver cirrhosis
were excluded. Enrolled subjects were categorized by phase of
CHB infection on the basis of the guidelines for the manage-
ment of CHB [1]: 108 subjects were in the IT phase (HBeAg-
positive with a high virus load (>5 × 107 IU/mL) and persistentlyClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectnormal ALT); 209 were in the IC phase (HBeAg positive with
an elevated ALT and a virus load >2000 IU/mL); 148 were in the
LR phase (HBeAg-negative with inactive viral replication (virus
load <2000 IU/mL) and persistently normal ALT); and 133 were
in the ENH phase (HBeAg negative with active viral replication
(virus load >2000 IU/mL) and elevated ALT).
The upper limit of normal of ALT was 40 U/L in this study.
Subjects in the IT group or the LR group had persistently
normal ALT for 6 months before enrollment. Forty-eight sub-
jects in the IC and ENH phases underwent liver biopsy, and
none presented evidence of liver cirrhosis. Plasma samples
were stored at −20°C until tested. The study was approved by
the institutional review board of Xijing Hospital of PLA and
Zhongshan Hospital in accordance with the Declaration of
Helsinki.
Laboratory measurements
The serum qAnti-HBc level was measured using a newly
developed double-sandwich immunoassay (dynamic range
0.08–2.5 IU/mL; Wantai, China), which was calibrated using the
World Health Organisation (WHO) standard (NIBSC, UK) [13]
(Supplementary Fig. S1). The samples were tested at dilutions of
1:10 to 1:100 000 (10-fold increase) if the Anti-HBc level was
>2.5 IU/mL. The HBsAg level was measured using a microplate
chemiluminescent assay (WTultra; dynamic range 0.02–100 IU/
mL; Wantai, China) calibrated using the WHO HBsAg standard.
The samples were tested at dilutions of 1:500 and 1:5000 if the
HBsAg was >100 IU/mL. HBeAg, anti-HBe and anti-HBs were
detected by Architect assays (Abbott Laboratories). The serum
HBV DNA level and the virus genotype were determined as
previously described [14].
Statistical analysis
The unpaired t test and a Kruskal-Wallis analysis of variance
were used to compare continuous variables, and the Mantel-
Haenszel χ2 test or Fisher’s exact test was used for categori-
cal variables. Linear regression models and Spearman’s rho tests
were used for correlation analyses. Receiver operating char-
acteristic (ROC) curves and areas under the ROC (AUROC)
curves were used to determine diagnostic accuracy. Differences
were considered signiﬁcant at a two-tailed p < 0.05. SPSS
software, v17.0, was used for all statistical analyses.ResultsAnti-HBc levels in subjects during different phases of
HBV infection
The characteristics of the individuals in the cross-sectional
cohort according to the phases of HBV infection areious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 197–203
CMI Song et al. qAnti-HBc level in natural history 199presented in Table 1. As shown in Fig. 1(a), HBsAg-positive
individuals (CHB group, n = 598, 3.74 ± 0.90 log10 IU/mL)
had signiﬁcantly higher (p < 0.001, approximately 1000-fold)
serum qAnti-HBc levels than those who were HBsAg negative
in both the OBI and PBI groups. ROC analysis was performed
to discriminate HBsAg status by anti-HBc level among all cases
(AUROC = 0.991, 95% conﬁdence interval 0.986–0.995,
p < 0.001, Fig. 1(b)), and the optimal cutoff was 89 IU/mL, with
a sensitivity of 95.8% and a speciﬁcity of 98.0%. Interestingly,
the OBI group (1.02 ± 0.76 log10 IU/mL) presented a signiﬁ-
cantly higher (p < 0.0001, Fig. 1(a)) average qAnti-HBc than the
PBI group (0.40 ± 0.62 log10 IU/mL). The AUROC of qAnti-
HBc for the diagnosis of OBI among HBsAg-negative in-
dividuals was 0.723 (95% conﬁdence interval 0.651–0.795,
p < 0.001), and the optimal cutoff was 6.6 IU/mL, with a
sensitivity of 60.7% and a speciﬁcity of 75.3% (Fig. 1(c)).
Among CHB subjects, the qAnti-HBc levels varied signiﬁ-
cantly and were widely distributed among different phases of
infection (Fig. 1(a)). The mean levels of qAnti-HBc were
3.03 ± 1.04 log10 IU/mL for IT subjects (median 1996 IU/mL,
range 1–26 980 IU/mL), 4.19 ± 0.62 log10 IU/mL for IC subjects
(median 20 553 IU/mL, range 131–177 680 IU/mL), 3.17 ± 0.70
log10 IU/mL for LR subjects (median 1997 IU/mL, range 8–34
744 IU/mL) and 4.27 ± 0.54 log10 IU/mL for ENH subjects
(median 21 852 IU/mL, range 96–174 960 IU/mL). The mean
Anti-HBc levels in the IC and ENH subjects were approximately
10-fold higher (p < 0.001) than those in both the IT and LR
subjects, whereas there was no signiﬁcant difference in the anti-
HBc level between IT and LR subjects (p 0.20) or between IC
and ENH subjects (p 0.22).
No signiﬁcant difference (p > 0.05) was observed between
men and women in each phase (Supplementary Fig. S2). UponTABLE 1. Baseline characteristics of the cross-sectional cohort acc
Characteristic
HBsAg negative individuals HBsAg
Past HBV
infection
(n [ 535)
Occult HBV
infection
(n [ 56)
Immun
toleran
(n [ 1
Age, years, median (range) 36 (1–55) 31 (19–54) 22 (4–
Sex, M/F 204/331 40/16 59/49
Genotype, B/Ca UD 20/36 52/56
HBeAg positive, n (%) 0 0 108 (10
Anti-HBe positive, n (%) 160 (29.9) 30 (53.5) 0
ALT, U/L, median (range) 14 (6–40) 21 (6–46) 26 (12–
AST, U/L, median (range) ND ND 22 (12–
TBIL, μM, median (range) ND ND 12 (5–
HBV DNA, Log10 IU/mL, mean ± SD
b UD 1.70 ± 0.84 8.42 ±
HBsAg, Log10 IU/mL, mean ± SD UD UD 4.85 ±
Anti-HBc, Log10 IU/mL, mean ± SD 0.40 ± 0.62 1.02 ± 0.76 3.03 ±
CHB, chronic hepatitis B; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; ALT, alanine am
total bilirubin; HBc, hepatitis B core protein; IC, immune clearance phase; LR, low-replicativ
aDue to the limit of low virus load, the virus genotype was unable to be determined in 1 IC s
infected with HBV genotype D; no other genotype was observed.
bTwo subjects had a virus load of <107 but >106 IU/mL with normal ALT was included in the I
the next 3 months. Four subjects with a virus load of >2000 IU/mL but <3000 IU/mL with pe
<2000 IU/mL but >1000 IU/mL with persistent ALT elevation were included in the IC (n =
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiologyvirus genotyping (Supplementary Fig. S3), subjects infected with
HBV genotype B had signiﬁcantly higher qAnti-HBc levels than
genotype C in the IT (p 0.02) and IC (p < 0.001) phases, while it
is signiﬁcantly lower in LR phase (p < 0.001). However, there
was no signiﬁcant difference (p 0.66) in ENH subjects. Among
HBsAg-negative subjects (Supplementary Fig. S4), the qAnti-
HBc levels seems to be higher in Anti-HBsAg-positive in-
dividuals in the PBI (n = 381) and OBI (n = 16) groups, but no
statistical signiﬁcance was observed (PBI p 0.06; OBI p 0.19). In
31 subjects, we observed S-region mutants in the OBI group
(Supplementary Table 1), whereas no signiﬁcant difference was
presented in qAnti-HBc levels between individuals with or
without mutation (p 0.35, Supplementary Fig. S4).
Correlation of qAnti-HBc with ALT in CHB subjects
Among all CHB subjects, univariate analysis (Table 2) revealed
that the qAnti-HBc level was strongly correlated with the levels
of ALT (R = 0.663, p < 0.001), aspartate aminotransferase
(AST) (R = 0.687, p < 0.001) and total bilirubin (R = 0.439,
p < 0.001); slightly correlated with age (R = 0.097, p 0.017) and
HBV DNA (R = 0.139, p 0.001); and not correlated with HBsAg
levels (R = −0.058, p 0.155). Multivariate regression analysis
(Table 2) revealed that the only independent factors associated
with qAnti-HBc were subjects’ ALT (β = 0.557, p < 0.001) and
AST (β = 0.286, p < 0.001). The correlation between the qAnti-
HBc level and the ALT level was signiﬁcant in both men
(R = 0.654, p < 0.001) and women (R = 0.628, p < 0.001), in
both genotype B (R = 0.675, p < 0.001) and genotype C
(R = 0.606, p < 0.001), and in both HBeAg-positive (R = 0.623,
p < 0.001) and HBeAg-negative subjects (R = 0.679, p < 0.001).
The correlation between qAnti-HBc and ALT was further
analysed (Fig. 2(a)). The average anti-HBc level successivelyording to CHB phase
positive (CHB)
p
e
ce
08)
Immune
clearance
(n [ 209)
Low
replicative
(n [ 148)
HBeAg-negative
hepatitis
(n [ 133)
54) 30 (10–68) 37 (4–75) 41 (14–82) <0.001
170/38 86/62 103/30 <0.001
93/115 53/60 63/66 0.53
0) 209 (100) 0 0 <0.001
19 (9.0) 132 (89.2) 107 (80.5) <0.001
39) 152 (40–3525) 21 (8–39) 238 (41–4093) <0.001
37) 94 (22–2261) 21 (9–46) 143 (27–2693) <0.001
21) 19 (4–646) 12 (3–21) 23 (5–586) <0.001
0.58 6.92 ± 1.52 2.67 ± 0.60 5.32 ± 1.57 <0.001
0.46 4.14 ± 0.95 2.88 ± 1.10 3.31 ± 1.04 <0.001
1.04 4.19 ± 0.62 3.17 ± 0.70 4.27 ± 0.54 <0.001
inotransferase; ND, no data; UD, undetectable; AST, aspartate aminotransferase; TBIL,
e phase; ENH, HBeAg-negative hepatitis phase.
ubject, 35 LR subjects and 3 ENH subjects. Only 1 ENH subject was determined to be
T group when the subjects had no subsequent DNA decrease or ALT elevation within
rsistent normal ALT were included in the LR group. Four subjects with a virus load of
1) or ENH (n = 3) group according to their HBeAg status.
and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 197–203
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FIG. 1. Distribution of serum anti-
HBc levels during different phases of
HBV infection. (a) Distribution of
serum anti-HBc levels during different
phases of HBV infection. Bars repre-
sent the mean with a 95% conﬁdence
interval. PBI, past hepatitis B virus
infection (n = 535); OBI, occult HBV
infection (n = 56); IT, immune toler-
ance phase (n = 108); IC, immune
clearance phase (n = 209); LR, low-
replicative phase (n = 148); ENH,
HBeAg-negative hepatitis phase
(n = 133). Receiver operating char-
acteristic analyses of the qAnti-HBc to
differentiate (b) HBsAg-positive in-
dividuals among all anti-HBc-positive
subjects and (c) OBI individuals
among HBsAg subjects.
200 Clinical Microbiology and Infection, Volume 21 Number 2, February 2015 CMIincreased (ptrend <0.001) with increasing ALT level among the
subjects in the ﬁrst 5 ALT strata (5 × the upper limit of
normal (ULN)), and it reached a plateau (p 0.95) in the subjects
with ALT >5 × ULN. When an ROC analysis was performed toTABLE 2. Correlation between anti-HBc levels of other
quantitative parameters in CHB subjects
Anti-HBc vs.:
Univariate analysis
Multivariate
analysis
R p β p
Age (years) 0.097 0.017 0.047 0.169
HBsAg (log10 IU/mL) −0.058 0.155 0.016 0.638
HBV DNA (log10 IU/mL) 0.139 0.001 −0.015 0.662
ALT, log2 (U/L) 0.663 <0.001 0.557 <0.001
AST, log2 (U/L) 0.687 <0.001 0.286 0.006
TBIL, log2 (μM) 0.439 <0.001 0.013 0.766
HBc, hepatitis B core protein; CHB, chronic hepatitis B; HBsAg, hepatitis B surface
antigen; HBV, hepatitis B virus; ALT, alanine aminotransferase; AST, aspartate
aminotransferase; TBIL, total bilirubin.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectdiscriminate the immunoactive phases (IC and ENH) on the
basis of qAnti-HBc level (Fig. 2)(b), the AUROC was 0.887
(95% conﬁdence interval 0.861–0.913, p < 0.001), and the
optimal cutoff was 7820 IU/mL, with a sensitivity of 79.8% and a
speciﬁcity of 85.2%.
Correlations between the qAnti-HBc level and other
clinical parameters in different CHB phases
As shown in Fig. 3, the qAnti-HBc level was positively associ-
ated with ALT and AST levels in all phases. The correlation of
the qAnti-HBc level and AST was statistically signiﬁcant in all
phases (R value 0.212–0.381, p < 0.01), and the correlation
with ALT was signiﬁcant in the IT, IC and ENH phases (R value
0.277–0.314, p < 0.01) but not in the LR phase (R = 0.149, p
0.071). The correlation between qAnti-HBc and HBsAg was
signiﬁcantly inverse in both the IT (R = −0.268, p < 0.001) and
IC (R = −0.297, p < 0.001) phases. Interestingly, it was positivelyious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 197–203
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FIG. 2. Association between the levels of anti-HBc and ALT in CHB subjects. (a) Average serum anti-HBc levels of CHB subjects according to the ALT
stratum. (b) ROC analysis of the anti-HBc level to discriminate ALT elevation (greater than the upper limit of normal) in CHB subjects. HBc, hepatitis B
core protein; ALT, alanine aminotransferase; CHB, chronic hepatitis B; ROC, receiver operating characteristic curve; AUROC, area under the ROC
curve.
CMI Song et al. qAnti-HBc level in natural history 201in the LR phase (R = 0.324, p < 0.001), whereas no association
was observed in the ENH phase (R = 0.047, p 0.588). More-
over, no signiﬁcant correlation was observed between the
qAnti-HBc level and the HBV DNA level.DiscussionHepatitis B core protein is the most immunogenic HBV antigen,
and its antibody can persist for a long time, irrespective of an
ongoing infection or virus clearance in an HBV-infected host.
Therefore, anti-HBc is well accepted as the most sensitive
marker of a history of HBV infection. Anti-HBc can be found in
serum shortly after the appearance of HBsAg in the initial phase
of HBV infection [15,16]. Nearly 100% of CHB subjects and
more than 90% of individuals with OBI are anti-HBc seropos-
itive [1]. Even in subjects who have completely recovered from
HBV infection after HBsAg loss, the persistence of anti-HBc
typically continues for 10 to 20 years or is lifelong. However,
little is known about the quantitative levels of anti-HBc during
the natural course of HBV infection. In this report, on the basis
of a cross-sectional study, we demonstrated that serum anti-
HBc quantiﬁcation was closely related to the HBsAg status
and hepatic inﬂammatory activities.
Signiﬁcant differences in serum qAnti-HBc levels were
observed across the different phases of HBV infection. Among
HBsAg-negative healthy individuals who had detectable anti-
HBc (>0.25 IU/mL), either with (OBI group) or without (PBI
group) a low level of serum HBV DNA, the qAnti-HBc levels
were dramatically lower (approximately 1000-fold) than inClinical Microbiology and Infection © 2014 European Society of Clinical Microbiologythose who were persistently HBsAg positive (CHB group). In
addition, the average qAnti-HBc level in the OBI group was
signiﬁcantly higher (approximately 4-fold) than that in the PBI
group. These ﬁndings suggest that virus antigens are the
essential factors that stimulate and maintain qAnti-HBc levels.
Hence, the qAnti-HBc measurement can be considered a
sentinel marker to trace the virus in the host in either overt
(HBsAg positive) or occult infections (HBsAg negative).
Immune-activated CHB subjects (IC or ENH) had signiﬁ-
cantly higher qAnti-HBc levels than immunotolerant and/or
inactive subjects, which suggests that the qAnti-HBc levels of
HBsAg-positive individuals are primarily determined by the host
immune status and hepatitis activities, and not by the levels of
HBV DNA or virus antigen. Theoretically, the circulatory HBV
core antigen (HBcAg) should affect the qAnti-HBc level.
Although HBcAg can be secreted into the blood as a compo-
nent of the virions, it is typically contained within the virus
envelope and is not readily accessible by B cells. This contain-
ment of HBcAg may provide a mechanistic explanation for the
low levels of anti-HBc but high levels of HBV DNA and HBsAg
in IT subjects with normal ALT levels. However, HBcAg can be
released from damaged infected hepatocytes and provide
potent antigenic stimulation to B cells to raise the qAnti-HBc
level. This assumption is supported by the observation of a
simultaneous increase in qAnti-HBc, ALT and AST in CHB
subjects. However, we cannot exclude the possibility that
excess qAnti-HBc antibodies may have direct cytolytic effects,
such as antibody-dependent cell-mediated cytotoxicity.
Consistent with this possibility, we observed that the peak anti-
HBc level might anticipate the ALT peak in some subjectsand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 197–203
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FIG. 3. Correlation between the qAnti-HBc level and ALT, AST and HBV DNA, and HBsAg in subjects in various infection phases. (a) IT phase. (b) IC
phase. (c) LR phase. (d) ENH phase. qAnti-HBc, quantitative anti–hepatitis B core protein; ALT, alanine aminotransferase; AST, aspartate amino-
transferase; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; IT, immune tolerance phase; IC, immune clearance phase; LR, low-replicative
phase; ENH, HBeAg-negative hepatitis phase.
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certain naïve B cells to rapidly proliferate and produce large
amounts of anti-HBc during the initial immune encounter.
Although these hypotheses both appear reasonable, the un-
derlying mechanisms that regulate the qAnti-HBc level in CHB
subjects require further exploration.
In CHB, ALT is a surrogate marker for the host immune
response against HBV because elevated ALT levels in CHB
subjects often result from cytolytic T cell–mediated hep-
atocytolysis. A high pretreatment ALT level, particularly when
more than 5 × ULN, is a strong predictor of HBeAg sero-
conversion in both interferon and nucleos(t)ide analogue
therapy [17,18]. In CHB subjects, the anti-HBc level wasClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectpositively correlated with the ALT level from 0.5 × ULN to
5 × ULN and reached a plateau at ALT levels greater than
5 × ULN, the cutoff value for treatment response prediction. It
may not be possible for the immune system to be overactivated
without limitation; therefore, ALT may be inﬂuenced by factors
in basic hepatic disease other than the anti-HBV cytotoxic T cell
response when ALT is higher than 5 × ULN. In that particular
scenario, qAnti-HBc may be a better marker of the host im-
mune response than ALT.
Our analyses established an anti-HBc level of >7820 IU/mL
as an optimal cutoff value for distinguishing subjects with or
without hepatitis activation. Although the ALT level is a
generally accepted surrogate marker to measure host immuneious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 197–203
CMI Song et al. qAnti-HBc level in natural history 203strength in CHB subjects, the half-life of serum ALT is shorter
than that of serum immunoglobulin antibodies. Therefore, in
clinical scenarios in which ALT levels return to normal, such as
during or at the end of treatment, the measurement of the
serum qAnti-HBc titre may provide additional information
about the host immune status.
In conclusion, the serum qAnti-HBc level is determined by
the host immune status and is strongly associated with hepatitis
activity in subjects with CHB. These ﬁndings suggest that
monitoring the dynamic changes in the qAnti-HBc level could
serve as a useful marker for clinicians to characterize the dis-
ease phase of subjects as well as their immune readiness against
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